Troy Wichterman Sells 4,151 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 4,151 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $103,775.00. Following the sale, the chief financial officer now owns 116,809 shares in the company, valued at approximately $2,920,225. This trade represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Troy Wichterman also recently made the following trade(s):

• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total transaction of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total transaction of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74.

BioLife Solutions Stock Down 0.2 %

Shares of BioLife Solutions stock opened at $25.00 on Friday. The stock’s 50-day moving average is $26.62 and its 200 day moving average is $25.50. BioLife Solutions, Inc. has a one year low of $14.84 and a one year high of $29.55. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -23.58 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the prior year, the business earned ($0.21) EPS. Equities research analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Institutional Investors Weigh In On BioLife Solutions

A number of large investors have recently bought and sold shares of BLFS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of BioLife Solutions by 13.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock valued at $1,835,000 after purchasing an additional 8,258 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in BioLife Solutions during the 4th quarter worth approximately $31,000. Point72 Asset Management L.P. bought a new position in BioLife Solutions in the fourth quarter worth approximately $11,113,000. ProShare Advisors LLC acquired a new stake in BioLife Solutions in the fourth quarter valued at approximately $282,000. Finally, Millennium Management LLC increased its holdings in shares of BioLife Solutions by 49.1% during the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after acquiring an additional 377,111 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on BLFS shares. KeyCorp raised their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Benchmark restated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. Northland Securities lifted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright increased their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.